These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 36937821)

  • 21. Treatment with TNF-α inhibitor infliximab might reduce hand osteoarthritis in patients with rheumatoid arthritis.
    Güler-Yüksel M; Allaart CF; Watt I; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; van Schaardenburg D; van Krugten MV; Dijkmans BA; Huizinga TW; Lems WF; Kloppenburg M
    Osteoarthritis Cartilage; 2010 Oct; 18(10):1256-62. PubMed ID: 20691795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States.
    Ding Q; Shiltz D; Hossami D; Konieczny AM
    Expert Rev Pharmacoecon Outcomes Res; 2022 Dec; 22(8):1231-1241. PubMed ID: 36004551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is non-biological treatment of rheumatoid arthritis as good as biologics?
    Parida JR; Misra DP; Wakhlu A; Agarwal V
    World J Orthop; 2015 Mar; 6(2):278-83. PubMed ID: 25793168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biologic drugs as analgesics for the management of osteoarthritis.
    Dimitroulas T; Lambe T; Klocke R; Kitas GD; Duarte RV
    Semin Arthritis Rheum; 2017 Jun; 46(6):687-691. PubMed ID: 28063649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands: results of the OA-TREAT study-a randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial.
    Kedor C; Detert J; Rau R; Wassenberg S; Listing J; Klaus P; Braun T; Hermann W; Weiner SM; Buttgereit F; Burmester GR
    RMD Open; 2021 Jul; 7(2):. PubMed ID: 34215704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging and New Treatment Options for Knee Osteoarthritis.
    Siddiq MAB; Clegg D; Jansen TL; Rasker JJ
    Curr Rheumatol Rev; 2022; 18(1):20-32. PubMed ID: 34784876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advanced application of stimuli-responsive drug delivery system for inflammatory arthritis treatment.
    Zhang M; Hu W; Cai C; Wu Y; Li J; Dong S
    Mater Today Bio; 2022 Mar; 14():100223. PubMed ID: 35243298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Latest insights in disease-modifying osteoarthritis drugs development.
    Li S; Cao P; Chen T; Ding C
    Ther Adv Musculoskelet Dis; 2023; 15():1759720X231169839. PubMed ID: 37197024
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reintroduction of immunosuppressive medications in pediatric rheumatology patients with histoplasmosis: a case series.
    Brown RA; Barbar-Smiley F; Yildirim-Toruner C; Ardura MI; Ardoin SP; Akoghlanian S
    Pediatr Rheumatol Online J; 2021 Jun; 19(1):84. PubMed ID: 34098976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of osteoarthritis and rheumatoid arthritis: prospects and possibilities.
    Blackburn WD
    Am J Med; 1996 Feb; 100(2A):24S-30S. PubMed ID: 8604723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients.
    Simon D; Kleyer A; Bayat S; Tascilar K; Kampylafka E; Meinderink T; Schuster L; Petrov R; Liphardt AM; Rech J; Schett G; Hueber AJ
    Arthritis Res Ther; 2019 Jul; 21(1):162. PubMed ID: 31269973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A retrospective observational study of glucosamine sulfate in addition to conventional therapy in hand osteoarthritis patients compared to conventional treatment alone.
    Tenti S; Giordano N; Mondanelli N; Giannotti S; Maheu E; Fioravanti A
    Aging Clin Exp Res; 2020 Jun; 32(6):1161-1172. PubMed ID: 31429006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Important determinants of the patient choice between TNF- vs. non-TNF Biologic disease-modifying anti-rheumatic drugs (DMARDs) for active rheumatoid arthritis (RA).
    Singh JA; Tornberg H; Goodman SM
    Joint Bone Spine; 2020 Jul; 87(4):307-313. PubMed ID: 32147565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Domains of quality of life affecting elderly patients with hand osteoarthritis: a qualitative study in the Asian perspective.
    Thumboo J; Wu L; Leung YY
    Int J Rheum Dis; 2017 Sep; 20(9):1105-1119. PubMed ID: 26990791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Role of Biologics in Rheumatoid Arthritis: A Narrative Review.
    Patel JP; Konanur Srinivasa NK; Gande A; Anusha M; Dar H; Baji DB
    Cureus; 2023 Jan; 15(1):e33293. PubMed ID: 36606106
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systemic rheumatic diseases: From biological agents to small molecules.
    Sarzi-Puttini P; Ceribelli A; Marotto D; Batticciotto A; Atzeni F
    Autoimmun Rev; 2019 Jun; 18(6):583-592. PubMed ID: 30959214
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
    Ruiz Garcia V; Burls A; Cabello JB; Vela Casasempere P; Bort-Marti S; Bernal JA
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD007649. PubMed ID: 28884785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Health status and perception of pain: a comparative study between female patients with hand osteoarthritis and rheumatoid arthritis.
    Slatkowsky-Christensen B; Mowinckel P; Kvien TK
    Scand J Rheumatol; 2009; 38(5):342-8. PubMed ID: 19585382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased radiographic progression of distal hand osteoarthritis occurring during biologic DMARD monotherapy for concomitant rheumatoid arthritis.
    Lechtenboehmer CA; Burkard T; Reichenbach S; Walker UA; Burden AM; Hügle T
    Arthritis Res Ther; 2021 Oct; 23(1):267. PubMed ID: 34702319
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.